The GLP-1 Price Traps That Cost People the Most

Almost nobody pays list price for a GLP-1. Ozempic lists around $969–$998 a month, Mounjaro around $1,069, Zepbound around $1,086, Wegovy around $1,349 — and between insurance, manufacturer cash programs, and assistance programs, most people pay a fraction of that.

But the routes to those lower numbers have conditions attached, and the conditions are where the money gets lost. These are the five that cost people the most, in rough order of how often they bite.

1. The copay card that doesn't work on your plan

Manufacturer copay savings cards are for commercial insurance only — an employer plan or a marketplace plan. Federal rules bar their use with Medicare, Medicaid, TRICARE, and other government programs.

This is the single most common cause of a surprise bill in this category, and the reason is structural: the cards are marketed broadly, the sign-up flow is frictionless, and the restriction is in the fine print. People on Medicare enroll, assume the discount applies, and find out at the pharmacy counter.

If you're on a government plan, the card is not your lever. Your levers are your plan copay, an exception or appeal if you're denied, and the manufacturer's cash and patient-assistance programs — which are separate from the copay card and do not carry the same restriction.

2. The intro price multiplied by twelve

Manufacturer cash programs advertise introductory pricing. Novo Nordisk's self-pay program lists an introductory price around $199/month for Wegovy; the maintenance figure is around $349/month. Ozempic's introductory self-pay starts near $199/month.

The trap is arithmetic. Introductory pricing is tied to starting doses and early fills — it is not a permanent maintenance price you can multiply by twelve to get an annual cost. Yet that multiplication is exactly what most "cheapest GLP-1" content does.

The two questions that fix it, asked of the program or pharmacy before you commit:

1. What do I pay at the dose I'm titrating toward?
2. How many fills does the introductory price cover?

Budget from those answers. The gap between an introductory monthly figure and a real annual cost is frequently thousands of dollars.

3. The discount that depends on your refill timing

This one is specific, easy to miss, and expensive.

Lilly's self-pay pricing for Zepbound at maintenance doses is $449/month for 7.5 mg and above — but only if you purchase each refill within 45 days of the previous fill. Miss that window and the same dose reverts to the regular self-pay price of $699/month for the 10, 12.5 and 15 mg strengths.

That's $250 more per month, for the identical medication at the identical dose — about $3,000 a year — determined entirely by refill timing.

The practical consequences:

• If you're comparing cash prices across products, compare the conditional price against the unconditional one honestly. Wegovy's cash maintenance pricing has no equivalent refill window.
• If your refills are irregular — travel, cash-flow timing, pharmacy delays — the option with the lower headline price may cost you more in practice.
• Set a calendar reminder tied to the window, not to when you run out.

4. Assuming compounded is obviously cheaper

Compounded semaglutide advertises around from about $69/month; compounded tirzepatide around from about $99/month. Against a four-figure list price, that looks decisive.

Two things narrow it more than people expect.

The advertised price is usually the starting dose, medication only. Real all-in cost adds the consultation or membership fee, lab work if required, higher pricing at maintenance strengths, and shipping. A headline figure can land far from what you actually pay by month three — and tirzepatide is worse for this than semaglutide, because it has more dose steps and compounded pricing is normally tiered by strength.

The brand cash programs came down. Zepbound self-pay starts at $299/month at the 2.5 mg starting dose and $399 at 5 mg. The oral Wegovy pill starts around $149/month. Those are FDA-approved products at manufacturer prices.

But the decisive factor isn't the monthly number at all — it's this:

Insurance essentially never covers compounded drugs. That means the cash price is the entire price, permanently. There is no copay to fall back on, no appeal route if it rises, and no manufacturer assistance program behind it. An approved product that gets covered can drop to a copay, and a denial can be fought.

So the honest comparison isn't "$200 versus $500." It's "$200 forever, guaranteed" versus "possibly a copay, possibly $500, with a route to argue about it." Find out what your plan would actually charge for the approved product before deciding on the headline.

And a note on terminology: compounded drugs are not FDA-approved, and their strength and purity are not FDA-verified. There is also no such thing as "compounded Ozempic," "compounded Zepbound," or "generic Ozempic" — those are branded products. A seller using that phrasing is either confused about what they're selling or hoping you are.

5. Paying cash before appealing a denial

A first denial is frequently a paperwork problem — a missing baseline weight, an undocumented prior therapy, a diagnosis code that never made it onto the form — not a final verdict on whether you qualify.

Switching straight to cash at that point can mean paying hundreds a month for a benefit you were entitled to.

The distinction that saves the most wasted effort is between a clinical decision and a benefit exclusion:

• If you were denied because you didn't meet criteria, or documentation was missing, or step therapy wasn't recorded — that's arguable, and the appeal machinery exists to fix it.
• If your plan simply excludes weight-loss drugs as a category, no medical evidence changes that. It's what your employer purchased. Recognize it early and change paths rather than appealing into a wall.

If it's the second, ask whether a non-weight indication applies to you — Wegovy carries an FDA cardiovascular-risk-reduction indication, and Zepbound one for moderate-to-severe obstructive sleep apnea. Neither is a weight-loss use, so coverage can be available through them even where weight-loss drugs are excluded.

Three phone calls worth making

Your plan. Is this drug on my formulary, at what tier, does it need prior authorization — and what's my 30-day retail copay versus a 90-day mail-order copay? That last comparison is frequently overlooked and frequently favorable.

Your prescriber's office. Will you file the prior authorization, and does my chart already document the diagnosis and prior therapies the criteria ask for? Missing documentation is the usual reason a first attempt fails.

The cash program. What do I pay at my expected maintenance dose — not the introductory price — and are there conditions attached to that number?

Prices above reflect manufacturer and program pricing as of July 2026 and change frequently. I keep the current figures and the full comparison of paths updated here: cheapest way to get Ozempic, compounded semaglutide cost, and how to appeal a GLP-1 denial.

Sources

• NovoCare — Wegovy and Ozempic self-pay and savings programs: https://www.novocare.com
• Zepbound coverage and savings — Eli Lilly: https://zepbound.lilly.com/coverage-savings
• LillyDirect self-pay pharmacy: https://lillydirect.lilly.com
• FDA — Compounding and the FDA: questions and answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• CMS — Part D appeals overview: https://www.cms.gov/medicare/appeals-grievances/prescription-drug/appeals-overview

Pricing checked July 2026. Manufacturer programs change their terms regularly — verify current figures and conditions directly before relying on them.

Educational information about pricing mechanics, not medical, legal, or financial advice.